BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1083 related articles for article (PubMed ID: 26469357)

  • 1. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study.
    Abdel-Razik A; Mousa N; Shabana W; Refaey M; ElMahdy Y; Elhelaly R; Elzehery R; Zalata K; Arafa M; Elbaz S; Hafez M; Awad M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):e1-9. PubMed ID: 26469357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil to lymphocyte ratio: a new marker for predicting steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease.
    Alkhouri N; Morris-Stiff G; Campbell C; Lopez R; Tamimi TA; Yerian L; Zein NN; Feldstein AE
    Liver Int; 2012 Feb; 32(2):297-302. PubMed ID: 22097893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative diagnostic accuracy of red cell distribution width-to-platelet ratio versus noninvasive fibrosis scores for the diagnosis of liver fibrosis in biopsy-proven nonalcoholic fatty liver disease.
    Cengiz M; Ozenirler S
    Eur J Gastroenterol Hepatol; 2015 Nov; 27(11):1293-9. PubMed ID: 26302023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.
    Lykiardopoulos B; Hagström H; Fredrikson M; Ignatova S; Stål P; Hultcrantz R; Ekstedt M; Kechagias S
    PLoS One; 2016; 11(12):e0167776. PubMed ID: 27936091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan.
    Kawamura Y; Ikeda K; Arase Y; Sorin Y; Fukushima T; Kunimoto H; Hosaka T; Kobayashi M; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Kumada H
    Hepatol Int; 2015 Apr; 9(2):269-77. PubMed ID: 25788193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Mansoor S; Yerian L; Kohli R; Xanthakos S; Angulo P; Ling S; Lopez R; Christine CK; Feldstein AE; Alkhouri N
    Dig Dis Sci; 2015 May; 60(5):1440-7. PubMed ID: 25540086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of a clinical score for the prediction of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease using routine parameters.
    Chunming L; Jianhui S; Hongguang Z; Chunwu Q; Xiaoyun H; Lijun Y; Xuejun Y
    Turk J Gastroenterol; 2015 Sep; 26(5):408-16. PubMed ID: 26215061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum β-trophin level as a new marker for noninvasive assessment of nonalcoholic fatty liver disease and liver fibrosis.
    Cengiz M; Ozenirler S; Kocabiyik M
    Eur J Gastroenterol Hepatol; 2016 Jan; 28(1):57-63. PubMed ID: 26513612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical usefulness of mean platelet volume and red blood cell distribution width to platelet ratio for predicting the severity of hepatic fibrosis in chronic hepatitis B virus patients.
    Karagoz E; Ulcay A; Tanoglu A; Kara M; Turhan V; Erdem H; Oncul O; Gorenek L
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1320-4. PubMed ID: 25210777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis.
    Cengiz M; Ozenirler S; Elbeg S
    J Gastroenterol Hepatol; 2015 Jul; 30(7):1190-6. PubMed ID: 25684563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.
    Kozumi K; Kodama T; Murai H; Sakane S; Govaere O; Cockell S; Motooka D; Kakita N; Yamada Y; Kondo Y; Tahata Y; Yamada R; Hikita H; Sakamori R; Kamada Y; Daly AK; Anstee QM; Tatsumi T; Morii E; Takehara T
    Hepatology; 2021 Nov; 74(5):2452-2466. PubMed ID: 34105780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver fibrosis markers of nonalcoholic steatohepatitis.
    Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M
    World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Accuracy of Platelet Count and Platelet Indices in Noninvasive Assessment of Fibrosis in Nonalcoholic Fatty Liver Disease Patients.
    Milovanovic Alempijevic T; Stojkovic Lalosevic M; Dumic I; Jocic N; Pavlovic Markovic A; Dragasevic S; Jovicic I; Lukic S; Popovic D; Milosavljevic T
    Can J Gastroenterol Hepatol; 2017; 2017():6070135. PubMed ID: 29464178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive estimation of disease activity and liver fibrosis in nonalcoholic fatty liver disease using anthropometric and biochemical characteristics, including insulin, insulin resistance, and 13C-methionine breath test.
    Korkmaz H; Unler GK; Gokturk HS; Schmidt WE; Kebapcilar L
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1137-43. PubMed ID: 26049707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.